• 1
    Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297: 267-277.
  • 2
    Neuhaus P, Riess H, Post S, et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC) [abstract]. J Clin Oncol. 2008; 26( 15S). Abstract 4504.
  • 3
    Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol. 1995; 15: 2403-2413.
  • 4
    Ruiz van Haperen VW, Veerman G, Vermorken JB, et al. 2′,2′-Difluoro-deoxycitidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol. 1993; 46: 762-766.
  • 5
    Plunkett W, Huang P, Searcy CE, et al. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996; 23: 3-15.
  • 6
    Lawrence TS, Change EY, Hohn TM, et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 1996; 34: 867-872.
  • 7
    Milas L, Fujii T, Hunter NR, et al. Enhancement of tumor radioresponse in vivo by gemcitabine, Cancer Res. 1999; 59: 107-114.
  • 8
    Mason KA, Milas L, Hunter NR, et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys. 1999; 44: 1125-1135.
  • 9
    Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 1999; 17: 2208-2212.
  • 10
    Murphy JD, Adusumilli S, Kent A, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007; 68: 801-808.
  • 11
    Van Laethem JL, Demols A, Gay F, et al. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study. Int J Radiat Oncol Biol Phys. 2003; 56: 974-980.
  • 12
    Demols A, Peeters M, Polus M, et al. Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian phase II study. Int J Radiat Oncol Biol Phys. 2005; 62: 1351-1356.
  • 13
    Van Laethem JL, Van Cutsem E, Hammel P, et al. Adjuvant chemotherapy alone versus chemoradiation after curative resection for pancreatic cancer: feasibility results of a randomised EORTC/FFCD/GERCOR phase II/III study (40013/22012/0304) [abstract]. J Clin Oncol. 2008; 26( 15S). Abstract 4514.
  • 14
    Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008; 299: 1019-1026.
  • 15
    Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009; 136: 187-195.
  • 16
    Marechal R, Mackey JR, Lai R, et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res. 2009; 15: 2913-2919.
  • 17
    Hatzis P, Al-Madhoon AS, Jullig M, Petrakis TG, Eriksson S, Talianidis I. The intracellular localization of deoxycytidine kinase. J Biol Chem. 1998; 273: 30239-30243.
  • 18
    Nakahira S, Nakamori S, Tsujie M, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer. 2007; 120: 1355-1363.
  • 19
    Itoi T, Sofuni A, Fukushima N, et al. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. J Gastroenterol. 2007; 42: 389-394.
  • 20
    Sebastiani V, Ricci F, Rubio-Viquiera B, et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res. 2006; 12: 2492-2497.
  • 21
    Hubeek I, Peters GJ, Broekhuizen AJ, et al. Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. J Clin Pathol. 2005; 58: 695-699.
  • 22
    Arner ES, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther. 1995; 67: 155-186.
  • 23
    Keszler G, Spasokoukotskaja T, Csapo Z, et al. Activation of deoxycytidine kinase in lymphocytes is calcium dependent and involves a conformational change detectable by native immunostaining. Biochem Pharmacol. 2004; 67: 947-955.
  • 24
    Spyrou G, Reichard P. Compartmentation of dCTP pools. Evidence from deoxyliponucleotide synthesis. J Biol Chem. 1987; 262: 16425-16432.
  • 25
    Spyrou G, Reichard P. Intracellular compartmentation of deoxycytidine nucleotide pools in S phase mouse 3T3 fibroblasts. J Biol Chem. 1989; 264: 960-964.
  • 26
    Spasokukotskaja T, Spyrou G, Staub M. Deoxycytidine is salvaged not only into DNA but also into phospholipid precursors. Biochem Biophys Res Commun. 1988; 155: 923-929.
  • 27
    Spasokukotskaja T, Taljanidisz J, Sasvari-Szekely M, Staub M. Deoxycytidine is salvaged not only into DNA but also into phospholipid precursors. III. dCOP-diacylglycerol formation in tonsillar lymphocytes. Biochem Biophys Res Commun. 1991; 174: 680-687.